T he prevalence of patients with resistant hypertension (RH) varies from 5% to 30%.
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Methods

Study Design
The PRAGUE-15 study was designed as an academic investigator-initiated, open-label, prospective, multicenter randomized trial (clinicaltrials. gov identifier: NCT 01560312). Patients with RH were randomized (in a 1:1 ratio) to either (1) a catheter-based RDN plus optimal antihypertensive treatment group (unchanged after randomization, thus including spironolactone only in rare cases where patients were already using the drug before entering the study) or to (2) an intensified pharmacological treatment group (PHAR), including spironolactone if tolerated and not contraindicated. Other medication changes after randomization were allowed only in clinically significant situations. All patients provided written informed consent. The study was approved by a multicenter Ethics Committee and by all 3 local institutional Ethics Committees. Enrollment in the study was prematurely halted (on ethical grounds) when the Symplicity HTN-3 trial interruption was announced because of failure to meet its primary efficacy end point. Therefore, the study was suspended on January 10, 2014 and an analysis of previously gathered data was performed. On the basis of the results of this analysis, it was decided to permanently terminate study enrollment and to complete the 3-years follow up on the previously enrolled patients as prescribed by the protocol. The exact study design ( Figure S1 in the online-only Data Supplement) and power and sample-size analysis has been previously reported. 7 Only patients with RH were included (with an office systolic BP >140 mm Hg after treatment with ≥3 antihypertensive drugs at optimal doses, including a diuretic). Secondary causes of hypertension (eg, primary aldosteronism, pheochromocytoma, Cushing syndrome, renal parenchymal disease, renovascular hypertension, drug-induced hypertension, or other conditions) were excluded in all subjects before randomization. True-RH was confirmed through 24-hour ABPM (average systolic BP >130 mm Hg) and assessment of treatment compliance (quantitative plasma drugs level measurements) before enrollment. 8, 9 Renal anatomy was evaluated during screening using computed tomography or magnetic resonance angiography. The differences in systolic and diastolic BP recorded by 24-hour ABPM between baseline and 6 months postrandomization were the primary end points of the study. In addition, office and 24-hour ABPM BP differences between baseline and 1-, 2-, and 3-year postrandomization were measured, as well as changes in standard clinical and laboratory parameters including renal function and postdenervation renal anatomy, analyzed using computed tomography or magnetic resonance angiography, 1 year after trial commencement. Another secondary end point was the effect of RDN on the medically treated group and the effect of spironolactone in the RDN group, 1 year after randomization. These variables measured after >6 months are not included in this article because the 3-years follow up is still ongoing and will not be completed until the end of 2016.
Three tertiary high volume centers in the Czech Republic enrolled 106 patients. After randomization, patients selected for RDN were maintained on baseline medical therapy for 1 year unless changes were considered clinically necessary. Patients selected for intensified medical treatment received baseline medical therapy plus spironolactone (25 mg daily), if tolerated, and if no contraindications were evident.
Procedures
The RDN procedure was performed by experienced interventional cardiologists or electrophysiologists using the Symplicity Renal Denervation System (Medtronic Inc, Mountain View, CA). In each of the 3 study centers, only 2 experienced interventionalists performed all procedures and all 6 physicians had previous experience with the system before the study started. Treatment involved ≥4 to 6 applications of low-power (8 W) radiofrequency energy to each renal artery. Each treatment was delivered in a helical fashion within the artery by rotating the catheter during pullback. The distance between ablation sites was ≈5 mm. All patients received intravenous heparin 100 U/kg of body weight at the beginning of the procedure. Procedures were performed under intravenous analgosedation, without endotracheal intubation.
BP Measurements
Office-measured BP values were obtained using validated BP monitors according to European Society of Hypertension and European Society of Cardiology Guidelines for management of arterial hypertension. 1 Twenty-four-hour ABPMs were obtained using an oscillometric device (SpaceLabs 90207/90217; SpaceLabs Medical, Redmond, WA).
Statistical Analysis
Stata version 13.1 (StataCorp LP, TX) was used to analyze the recorded data. The analysis included all randomized participants for whom data were available and was performed using the intention-to-treat principle. Descriptive statistics were used to summarize characteristics of study participants. For continuous variables, the Student t test was used for normally distributed data and the Mann-Whitney U test for non-normally distributed data. The Fisher exact test was used for proportions. Longitudinal data analysis (comparison of baseline and 6-month data), including adjustment for the number of antihypertensives and use of aldosterone antagonists, was performed by generalized estimating equations with an unstructured correlation matrix to adjust for correlations over the assessment time points. P<0.05 was considered statistically significant. All reported subgroup analyses were prespecified.
Results
One hundred six patients fulfilled all entry criteria and were randomized. Fifty-two patients were randomized to RDN and 54 to PHAR group. Baseline office BP was 159±19/92±14 mm Hg (while on 5.1±1.2 antihypertensive drugs) in the RDN group and 155±17/89±14 mm Hg (while on 5.4±1.2 antihypertensive drugs) in the PHAR group. Baseline 24-hour average BP was 149±12/86±10 mm Hg in the RDN group and 147±13/84±10 in the PHAR group. See Tables 1-3 for the baseline characteristics of study participants and 6-month results. There were no significant baseline differences between groups in most of the studied parameters, however, body mass index was an exception (31.2 in RDN versus 33.4 in PHAR, P=0.01). This difference remained unchanged after 6 months.
Twenty-Four-Hour ABPM
A significant reduction in 24-hour average systolic BP after 6 months (−8.6 mm Hg in RDN; P<0.001 versus −8.1 mm Hg in PHAR; P=0.001) was observed, which was comparable in both groups. Similarly, a significant decrease in the 24-hour average diastolic BP (−5.7 mm Hg in RDN; P<0.001 versus −4.5 mm Hg in PHAR; P<0.001) was also observed and was comparable in both groups (Figure 1 ). Figure 2 ). Between-group differences in change were not significant.
Office BP
Heart Rate
A significant reduction in heart rate was recorded in RDN (−3.4 beats per minute; P=0.02) with no significant between-group differences when compared with PHAR. However, nonsignificant changes in the 24-hour heart rate were present. Differences in the studied parameters are summarized in Table 3 .
Medication
The average number of antihypertensive drugs used was significantly higher after 6 months in PHAR (+0.3 drugs; P<0.001) group, which reflected the increased number of patients on spironolactone (+20; P<0.001). See Tables 4 and S1 for the characteristics of antihypertensive treatment and changes. In the PHAR group, the spironolactone treatment was, for several reasons, not possible in 21 patients (see Table 5 for side effects and adverse events). The discontinuation was initiated before the 6-month visit. An alternative option (eplerenone) was offered when possible, but was refused by all patients because of the financial costs of the drug. After adjustment for the number of drugs and aldosterone antagonist use, the 24-hour systolic BP reduction remained significant in both groups (P<0.001) and between-group differences remained nonsignificant (P=0.46).
Similarly, other differences in BP parameters did not change after this adjustment. Furthermore, adjustment for body mass index did not influence the significance of BP differences.
Predictors of BP Response
Logistic regression analysis showed that the main predictors of successful RDN, defined as ≥10 mm Hg decrease in systolic 24-hour BP, were related to the total number of ablations, day systolic BP and day heart rate. After adjustment, day systolic BP remained the main predictor. Linear regression analysis showed similar results, with day systolic BP and day heart rate as the main predictors after adjustment. See Table  S2 for results from the logistic and linear regression analysis and Tables S3 and S4 for the response rates in both groups.
Biochemistry
Several laboratory changes were observed. Significant sodium level decline was observed in the PHAR group, while no significant reduction was observed in the RDN group, and no between-group differences in change were present after 6 months. A significant increase in serum creatinine levels was observed in the PHAR group (+5.3 µmol/L; P=0.048). Between-group difference in change had borderline statistical significance (P=0.06). A parallel decrease of creatinine clearance was also observed (−0.3; P=0.048), with similar between-group difference in change (P=0.06). A significant Values are shown as means±SD or medians (interquartile range) or absolute numbers. BP indicates blood pressure; CI, confidence interval; PHAR, intensified pharmacological treatment; and RDN, renal-artery denervation. A P value <0.05 was considered statistically significant (in bold). by guest on July 11, 2017 http://hyper.ahajournals.org/ Downloaded from increase in potassium levels (+0.2; P=0.02) was observed, but only in the subgroup where spironolactone was added and continued (see Tables S7 and S8 for the subanalysis of the PHAR group according to spironolactone addition and its continuation).
Procedural Characteristics
The mean number of successful ablations (lasting ≥120 s) in right renal arteries was 5.27±2.33 and 5.48±1.65 in the left. We did not reach the recommended number of ablations (≥4 per side) in 7 patients, 2 patients out of that number had unilateral ablations for anatomic reasons. The mean value of the impedance drop was 14.63±4.05% on the right side and 13.97±3.37% on the left side. The mean tissue temperature after energy delivery was 55.5±10.18°C on the right side and 55.9±6.4°C on the left side.
See Tables S5 and S6 for the subanalysis of the RDN group according to the number of ablations per side.
Safety
We recently published that no significant complications were recorded in association with the RDN procedure, 10 see Table 5 for minor side effects and adverse events. None of these led to clinically significant consequences for the patients. One case of renal artery dissection was resolved by immediate stenting. All spasms were fully treated or reduced through intra-arterial administration of nitrates. There was 1 ischemic stroke and 1 myocardial infarction (without ST elevations) in the RDN group during the 6-month follow up; and 1 case of unstable angina was observed in the PHAR group. No deaths occurred during follow-up.
Discussion
This randomized, prospective study showed that in the settings of true-RH, RDN is not superior to intensified PHAR over a period of 6 months. Twenty-four-hour ABPM parameters, Figure 1 . Ambulatory 24-hour average blood pressure (BP) changes. Significant 24-hour average BP changes from baseline to 6 months were observed in both groups. However, between-group differences in change were not significant. CI indicates confidence interval; PHAR, intensified pharmacological treatment; and RDN, renal-artery denervation. as well as office BP values were comparably affected in both treatment arms, without marked between-group differences.
The study was designed to assess the efficacy of RDN as a treatment for true-RH. Discrepant results in RDN efficacy have been observed in previous studies. 2, 4, 6, 11, 12 Several differences in the methodology of these trials might have contributed to the disparity of results. Currently, the Symplicity HTN-3 study, which was recently published, is considered the most robust RDN study. 13 Despite the fact that our study was smaller and a sham procedure was not part of our protocol, our study has several potential advantages. First, we totally excluded the possibility of secondary hypertension in all study participants before allowing enrollment in the PRAGUE-15 study, and every patient underwent a thorough examination in a hypertension center. 8 Second, compliance with treatment was fully confirmed in all patients, using quantitative measurements of plasma drug levels, before enrollment. To our knowledge, this was not performed in any prior study that tested the effect of RDN on RH; although, there was 1 smaller study that used witnessed intake of medication to systematically measure treatment compliance. 6 Currently, urine or plasma drug levels are considered the most reliable methods for identifying noncompliance. 9, 14 On the basis of a previous study, treatment noncompliance is a common cause of inadequate BP control. 8, 9 Furthermore, as only pharmacologically treated hypertensive patients enter RDN studies, the issue of compliance is crucial to identify the actual effects of RDN. When assessing additive therapeutic modalities, such as RDN, patient compliance with the basic therapeutic modality, in this case pharmacological treatment, is critical. Otherwise, it is impossible to know if the observed BP changes were associated with RDN or were the result of variations in treatment compliance. Sham procedures can eliminate possible placebo and Hawthorne effects; however, it does not eliminate variations as a result of treatment adherence, which would necessitate using RDN only on untreated hypertensive patients. Compliance together with a thorough examination at a hypertension center before enrollment, ensured selection of trueresistant essential hypertensive patients for the PRAGUE-15 study. This design might explain the relatively low baseline values of office BP, as well as 24-hour ABPM compared with all other Symplicity trials.
2-4,13 However, our BP values are comparable with the study that systematically tested for a secondary cause of hypertension before enrollment and monitored treatment noncompliance using witnessed intake of medication. 6 Additional clinical value came from comparing RDN with intensified pharmacological treatment, which included spironolactone. It has been shown that spironolactone effectively reduces BP in resistant hypertensive patients. 15, 16 The effect of spironolactone in those who did not respond to RDN will be evaluated 1 year after randomization.
There are several potential factors influencing the BP reduction observed in both groups. Despite the fact, that computed tomography or magnetic resonance angiography was used to confirm anatomic eligibility, we did not reach the recommended number of ablations (≥4 per side) in 7 patients (13.5%). Because the study was performed using Figure 2 . Office blood pressure (BP) changes. Significant office BP changes from baseline to 6 months were observed in both groups. However, between-group differences in change were not significant. CI indicates confidence interval; PHAR, intensified pharmacological treatment; and RDN, renal-artery denervation. intention-to-treat principles, we did not exclude these patients from the analysis. Furthermore, our results indicate that the number of ablations might be a possible predictor of response to RDN. This fact might support the efficacy of the method and might suggest a need to perform even more ablations. However, at the time of study preparation and according to the Symplicity HTN-1 and 2 trials, 3,4 4 to 6 ablations were recommended, which were achieved in most of the patients. Furthermore, there was no evidence of a correlation between the number of ablations and the response to RDN at that time. A subanalysis of patients, with 4 to 6 ablations, showed that BP changes are more pronounced in this group. Further analyses on large samples would be necessary to confirm these findings and to identify patients who would benefit from RDN. However, these results might suggest that new, multielectrode systems could be more effective in producing a decline in BP.
Similarly, there are several important factors influencing BP reduction in the PHAR group. First, 13 patients in PHAR (14 in RDN) entered the study already taking an aldosterone antagonist. However, we considered it unethical to withdraw this potent drug before randomization. Second, in another 21 patients spironolactone treatment was discontinued during the 6-month follow up because of intolerance or hyperkalemia. Finally, medication changes were necessary in this group more often to maintain treatment safety (to prevent hyperkalemia and worsening of renal function), for example, ACEi/ sartan/amiloride dose reductions. Another reason for therapy reduction was symptomatic BP decline. When we evaluated the effect in patients in whom spironolactone was added after enrollment and continued for 6 months, we observed a 12 mm Hg reduction in systolic 24-hour average BP. The rate of intolerance of spironolactone observed in our study (39%) was higher than generally observed (10% to 30%). 17 The psychological effect of expecting (and possibly hoping for) crossover when not reaching the BP goal might be one of the explanations. The subanalysis of the PHAR group indicates that BP decline was mostly driven by patients in whom spironolactone was added and continued.
Apart from BP changes, a significant reduction in heart rate was observed in RDN. This might be a consequence of a lowered whole-body sympathetic activity mediated by a reduction of renal afferent nerve activity. Heart rate changes, independent of BP changes, after RDN were reported previously. 18 Several other laboratory changes were recorded in the PHAR group, mostly associated with spironolactone treatment. Significant decrease in plasma sodium was present. Slight, but significant, plasma potassium level increase was recorded in the subgroup of PHAR where spironolactone was added and continued. We observed a significant increase in serum creatinine level and a parallel decrease of creatinine clearance in the PHAR group, which might have also been the result of spironolactone treatment. Between-group differences in change were borderline, but not significant. Furthermore, spironolactone treatment led to significant worsening of renal function (without the need of dialysis), which persisted after its discontinuation, only in 1 patient with diabetic nephropathy. All the observed spironolactone side effects were well known and have been previously described; as expected this medication required careful and regular monitoring. 15, 16 However, further follow-up would be necessary to evaluate long-term safety relative to renal function, especially in RDN.
There are several possible limitations to our study. Potential disadvantages of not performing a sham procedure have already been discussed. However, we consider an invasive pseudoprocedure including sedation, with all its possible side effects, to be problematic. Another possible limitation was the relatively small number of participants. However, it was expected that careful screening of participants would significantly reduce the number of eligible patients for RDN. 8, 19 That was the reason why the initial study design was for only 120 patients. Post hoc power analysis showed that it is possible to identify between-group differences of 6.9 mm Hg (when P=0.05; power=0.08) for systolic 24-hour BP and 5.5 mm Hg for diastolic 24-hour BP with the current number of enrolled patients. The number of patients enrolled to our study was comparable with the number enrolled in Symplicity HTN-2.
Perspectives
This study shows that over a period of 6 months, RDN is safe, with no serious side effects. However, in the settings of true-RH with confirmed compliance, it is not superior to intensified pharmacological treatment including the use of spironolactone. Further studies on a larger sample of subjects with true-RH would be appropriate before the final role of denervation is established. Currently, renal denervation is not a routine therapeutic approach in patients with severe hypertension and should be reserved for use only in hypertension centers, and only after a thorough examination.
Sources of Funding
What Is New?
• In the settings of true-resistant hypertension with confirmed compliance, renal denervation is not superior to intensified pharmacological treatment.
What Is Relevant?
• Renal denervation should be reserved only for true-resistant hypertension patients with excluded secondary hypertension and confirmed compliance to treatment.
• Renal denervation does not represent routine therapeutic approach in patients with severe hypertension and should be applied only in hypertension centers after thorough examination.
Summary
Renal denervation leads to a significant blood pressure reduction (office, as well as 24-hour ambulatory blood pressure monitoring) over a 6 months period in the settings of true-resistant hypertension. However, this decline is comparable with intensified pharmacological treatment, including spironolactone. 
